7/8/03

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number (Optional) 104914-159	Application Number ~~Not Yet Assigned~~ 10/615,518
	Applicant, Jeffrey M. Leiden	
	Filing Date 7/8/2003	Group Art Unit 1632 ~~Not Yet Assigned~~

U. S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AMF	5,962,313	10/5/99	Podsakoff *et al.*			
	5,858,351	1/12/99	Podsakoff *et al.*			
	5,846,528	12/8/98	Podsakoff *et al.*			
	5,693,622	12/2/97	Wolff *et al.*			
AMF	5,580,859	12/3/96	Felgner *et al.*			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES	Translation NO
AMF	WO 95/13376	5/18/95	WO				

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

AMF		Barr *et al.* (1995) Gene Ther. 2:151-155, "Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains".
		Barr *et al.* (1994) Gene Ther. 1:51-58, "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus".
		Barr and Leiden (1991) Science 254:1507-1509, "Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts".
		Brody *et al.* (1994) Human Gene Ther. 5:821-836, "Acute Responses of Non-Human Primates to Airway Delivery of an Adenovirus Vector Containing the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA".
		Dai *et al.* (1995) PNAS USA 92:1401-5, "Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression".
		Dai *et al.* (1992) PNAS USA 89:10892-5, "Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo".
		Dhawan *et al.* (1991) Science 254:1509-1512, "Systemic Delivery of Human Growth Hormone by Injection of Genetically Engineered Myoblasts".
AMF		Engelhardt *et al.* (1994) Hum.Gene Ther. 5:1217-29, "Prolonged Transgene Expression in Cotton Rat Lung with Recombinant Adenoviruses Defective in E2a"
		EXAMINER /Anne Marie Falk/ DATE CONSIDERED 02/04/2007
		EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number (Optional) 104914-159	Application Number ~~Not Yet Assigned~~ 10/615,518
	Applicant, Jeffrey M. Leiden	
	Filing Date 7/8/2003	Group Art Unit 1632 ~~Not Yet Assigned~~

AMF		Friedmann, T. (1997) Sci. Am. 96-101, "Overcoming the obstacles to gene therapy".
		Hamamori *et al.* (1995) J. Clin. Invest. 95:1808-1813, "Myoblast Transfer of Human Erythropoietin Gene in a Mouse Model of Renal Failure".
		Hamamori *et al.* (1994) Hum. Gene Ther. 5:1349-1356, "Persistent Erythropoiesis by Myoblast transfer of Erythropoietin cDNA".
		Kass *et al.* (1994) Gene Ther. 1:395-402, "The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer".
		Kay *et al.* (1994) PNAS USA 91:2353-7, "In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs".
		Lemarchand *et al.* (1992) PNAS USA 89:6482-6, "Adenovirus-mediated transfer of a recombinant human α1-antitrypsin cDNA to human endothelial cells".
		Manthorpe *et al.* (1993) Hum. Gene Ther. 4:419-31, "Gene Therapy by Intramuscular Injection of Plasmid DNA: Studies on Firefly Luciferase Gene Expression in Mice".
		Mastrangeli *et al.* (1996) Hum. Gene Ther. 7:79-87, "'Sero-Switch' Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype".
		Mendell *et al.* (1995) N. Engl. J. Med. 333:832-8, "Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy".
		Morgan, J.E. (1994) Hum. Gene Ther. 5:165-73, "Cell and Gene Therapy in Duchenne Muscular Dystrophy".
		Orkin and Motulsky (1995) "Report and recommendations of the panel to assess the NIH investment in research on gene therapy".
		Osborne *et al.* (1995) Proc. Natl. Acad. Sci. USA 92:8055-8058, "Gene therapy for long-term expression in erythropoietin in rats".
		Partridge *et al.* (1989) Nature 337:176-179, "Conversion of mdx myofibres from dystrophin-negative to –positive by injection of normal myoblasts".
		Raz *et al.* (1993) Proc. Natl. Acad. Sci. USA 90:4523-4527, "Systemic immunological effects of cytokine genes injected into skeletal muscle".
↓		Rosenfeld *et al.* (1991) Science 252:431-434, "Adenovirus-Mediated Transfer of a Recombinant α1-Antitrypsin Gene to the Lung Epithelium in Vivo".
AMF		Setoguchi *et al.* (1994) Blood 84:2946, "Stimulation of Erythropoiesis by In Vivo Gene Therapy: Physiologic Consequences of Transfer of the Human Erythropoietin Gene to Experimental Animals Using an Adenovirus Vector".
	EXAMINER /Anne Marie Falk/	DATE CONSIDERED 02/04/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Docket Number (Optional) 104914-159	Application Number ~~Not Yet Assigned~~ 10/615,518
	Applicant, Jeffrey M. Leiden	
	Filing Date 7/8/2003	Group Art Unit 1632 ~~Not Yet Assigned~~

AMF		Tripathy *et al.* (1996) Nature Med. 2:545-550, "Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors".
		Tripathy *et al.* (1994) Proc. Natl. Acad. Sci. USA 91:11557-11561, "Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus".
		Verma *et al.* (1997) Nature 389:239-242, "Gene therapy – promises, problems and prospects".
		Vincent *et al.* (1993) Nat. Genet. 5:130-4, "Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene".
		Wolff *et al.* (1992) Hum. Mol. Gen. 1:363-9, "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle".
		Wolff *et al.* (1990) Science 247:1465-1468, "Direct Gene Transfer into Mouse Muscle in Vivo".
		Yang *et al.* (1996) Gene Ther. 3:137-144, "Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo".
		Yang *et al.* (1995) J. Virol. 69:2004-15, "Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses".
		Yang *et al.* (1995) J. Immunol. 155(5):2564-2570, "Clearance of Adenovirus-Infected Hepatocytes by MHC Class 1-Restricted $CD4^+$CTLs in Vivo."
		Yang *et al.* (1994) Immunity 1:433-42, "MHC Class 1-Restricted Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice Infected with E1-Deleted Recombinant Adenoviruses".
		Yang *et al.* (1994) Proc. Natl. Acad. Sci. USA 91:4407-4411, "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy".
AMF		Yao, S. and Kurachi, K. (1992) PNAS USA 9:3357-3361, "Expression of human factor IX in mice after injection of genetically modified myoblasts".
	EXAMINER /Anne Marie Falk/	DATE CONSIDERED 02/04/2007
	EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy with next communication to applicant.	